<DOC>
	<DOC>NCT01545791</DOC>
	<brief_summary>This study is conducted in Europe. The aim of the study is to observe the safety of insulin detemir (Levemir®) in patients with type 1 and type 2 diabetes patients.</brief_summary>
	<brief_title>Observational Study to Evaluate the Safety of Levemir® in Patients With Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Any patient with type 1 or type 2 diabetes mellitus, including newly diagnosed patients who had never received insulin or an insulin analogue before Patients whom the physician considered might be noncompliant for any reason; for example, uncooperative attitude, inability to return for the final visit and similar Patients previously enrolled in this study Patients with a hypersensitivity to insulin detemir</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>110 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>